Blockchain Registration Transaction Record

Regentis CEO Discusses GelrinC Progress and Market Potential on BioMedWire Podcast

Regentis Biomaterials CEO Dr. Ehud Geller discusses GelrinC(R) for knee cartilage repair, European approval, U.S. pivotal trial, and a 470,000-case U.S. market opportunity.

The development of GelrinC(R) could revolutionize the treatment of cartilage knee injuries, offering a much-needed off-the-shelf solution for the approximately 470,000 untreated cases annually in the U.S. If successful, it may reduce the need for invasive surgeries and provide a more accessible option for patients. For investors, Regentis' advancements in clinical trials and European commercialization efforts could translate into significant market opportunities and potential revenue growth. As the regenerative medicine field continues to evolve, Regentis' progress highlights the growing intersection of biotechnology and orthopedic care, with implications for patient outcomes and the broader healthcare industry.